| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11060-013-1139-X |
| P698 | PubMed publication ID | 23673513 |
| P2093 | author name string | Kevin Murphy | |
| Bob S Carter | |||
| Clark C Chen | |||
| Joshua Lawson | |||
| Michelle Russell | |||
| John F Alksne | |||
| David D Gonda | |||
| Brent Rose | |||
| Daniel J Scanderbeg | |||
| J Dawn Waters | |||
| P2860 | cites work | Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma | Q24612429 |
| MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineli | Q30660196 | ||
| GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis | Q31035468 | ||
| Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial | Q33453675 | ||
| Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma | Q33574572 | ||
| Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis | Q33957687 | ||
| Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03 | Q34033710 | ||
| A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival | Q34108339 | ||
| Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study | Q34239497 | ||
| The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine | Q34786726 | ||
| DNA damage response and repair: insights into strategies for radiation sensitization of gliomas | Q35608458 | ||
| The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme | Q35688316 | ||
| Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects | Q35951631 | ||
| Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas | Q37036914 | ||
| The linear-quadratic formula and progress in fractionated radiotherapy | Q38678064 | ||
| The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model | Q39385101 | ||
| In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide | Q40017220 | ||
| Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage | Q41015308 | ||
| Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme | Q42749632 | ||
| High activity iodine-125 interstitial implant for gliomas | Q43529193 | ||
| GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study | Q44048453 | ||
| Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protoco | Q45090505 | ||
| Interstitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience | Q46087739 | ||
| An extent of resection threshold for newly diagnosed glioblastomas | Q46126935 | ||
| Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme | Q46225674 | ||
| External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2 gliomas: NCOG study 6H-82-2 | Q46293640 | ||
| Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas | Q46732494 | ||
| Long term results of stereotactic brachytherapy used in the initial treatment of patients with glioblastomas | Q48105384 | ||
| Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme | Q48162974 | ||
| An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. | Q48224367 | ||
| Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 | ||
| Imaging response in malignant glioma, RTOG 90-06. | Q48284976 | ||
| Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials | Q48286137 | ||
| Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins | Q48367095 | ||
| Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma | Q48404651 | ||
| A pilot study of brain tumour growth between radiotherapy planning and delivery | Q48624764 | ||
| Radiosurgery and accelerated radiotherapy for patients with glioblastoma | Q48716370 | ||
| Dosimetric characteristics of the MammoSite RTS, a new breast brachytherapy applicator. | Q52121161 | ||
| Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. | Q55470774 | ||
| Brachytherapy: Results of two different therapy strategies for patients with primary glioblastoma multiforme. | Q55475498 | ||
| Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. | Q55475674 | ||
| Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources | Q55489010 | ||
| P433 | issue | 3 | |
| P921 | main subject | temozolomide | Q425088 |
| brachytherapy | Q896687 | ||
| P304 | page(s) | 467-477 | |
| P577 | publication date | 2013-05-15 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Immediate post-operative brachytherapy prior to irradiation and temozolomide for newly diagnosed glioblastoma | |
| P478 | volume | 113 |
| Q35701142 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma |
| Q38784169 | Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers |
| Q55072630 | Effects of combined radiosurgery and temozolomide therapy on epidermal growth factor receptor and variant III in glioblastoma multiforme. |
| Q27027730 | Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review |
| Q38834847 | The role of brachytherapy in the treatment of glioblastoma multiforme |
Search more.